865 million yuan annual salary!

For many pharmaceutical companies, the key word in 2020 is the new crown epidemic.

Obviously, the pandemic of the new crown epidemic has brought some impact on the salary of global pharmaceutical giant CEOs.

2020 global pharmaceutical giant CEO salary TOP15

According to Fierce Pharma's statistics, among the 15 highest paid biopharmaceutical company CEOs in 2020, Regeneron CEO Leonard Schleifer won the crown with an astonishing $135 million (about 865 million yuan) annual salary, and is the second Novastar.

As in 2019, there are still no female executives in this year's Top15.

At the same time, the CEOs of Sanofi, Roche and Novartis have apparently been absent for the second consecutive year.

In general, CEOs of companies involved in the development of new crown vaccines and drugs will receive higher salaries, such as Regeneron and Novavacs.

AbbVie's Richard Gonzales salary rose 11% year-on-year compared to 2019; CEOs from BioMarin and Horizon Therapeutics are on the list for the first time.

Similarly, there are also some corporate compensation plans that have aroused the anger of their investors, such as Johnson & Johnson's executive compensation and AstraZeneca's executive bonus plan.

01 Regenerant Leonard Schleifer: US$135 million

New crown epidemic "players" generally paid high salaries in 2020, and the remuneration of the CEO of Regenerating Yuan may set a high benchmark for the next few years.

In fact, the salary of Regeneron’s CEO is similar to that of other biopharmaceutical company CEOs: a salary of $1.

And Schleifer's salary, in 2016-2019, basically maintained in the range of 20-30 million US dollars.

Regeneron stated in its annual report that last year it gave the company's two top executives a five-year stock award, and will not issue more stock awards until December 2025.

As we all know, Regeneron has played an important role in the United States' response to the new crown epidemic.

In April of this year, Regeneron released the results of phase III experiments on the use of antibody therapy to prevent infection with the new coronavirus for high-risk populations, showing that the drug can effectively reduce the risk of symptomatic infection in subjects in the case of family infections, and Can effectively shorten the time required for recovery after infection.

02 Novavax Stanley Erck: 48.

Erck received a salary of $48 million in 2020.
From the perspective of the salary structure, his total compensation includes a salary of 650,000 U.
S.
dollars and more than 46.
8 million U.
S.
dollars in stock and option awards.
Erck also received a cash prize of approximately $600,000.
Novavax attributed Erck's high salary to the company's progress in new crown vaccine candidates.
Novavax explained that the company must maintain a compensation plan to provide the necessary incentives to retain key employees and avoid interrupting the company's vaccine work.

As a US vaccine research and development company, before the outbreak of the epidemic, Novavacs had not successfully approved a vaccine in its 33-year history, and its clinical trials had repeatedly failed, and it was on the verge of delisting.

At the beginning of last year, Novavax started the new crown vaccine research and development plan, and now there are promising vaccine candidates about to be unveiled.
Although Novavax has not yet received approval for the vaccine, the biotech company has been busy building its manufacturing network and negotiating supply agreements.

On March 11 this year, Novavax announced the final test results.
The third phase of clinical trials conducted in the United Kingdom on 15,000 subjects aged 18-84 showed that Novavax vaccine is effective against COVID- 19 The original strain has a protective power of 96.
4%, making it the most effective and safest new crown vaccine at present.

Novavax said that it is expected to be approved for use in the United States as soon as May, becoming the fourth vaccine approved in the United States after Johnson & Johnson vaccine.
At the end of March, the British government announced that it would order 60 million doses of Novavax's new crown vaccine.
GSK has agreed to support the production and packaging process of the vaccine developed by Novavax.
At the same time, the Hong Kong Special Administrative Region government of China also intends to order the vaccine.

03 Johnson & Johnson Alex Gorsky: 29.
58 million US dollars

Although Johnson & Johnson failed to achieve sales and adjusted earnings targets, the company's CEO Alex Gorsky still achieved a 17% salary increase in 2020.

Johnson & Johnson CEO Alex Gorsky is already a frequent visitor to the list of CEOs of the world's highest paid pharmaceutical company.
Gorsky's total compensation was US$29.
58 million, an increase of 17% compared to 2019's compensation.

Although Johnson & Johnson failed to achieve sales and adjusted earnings targets, Gorsky still received a salary increase.
Johnson & Johnson pointed out that the predicament of its medical equipment division during the pandemic was the main reason for the decline in sales.
As the pandemic of the new crown pneumonia epidemic spreads around the world, hospitals have to cancel elective treatment procedures and give priority to treating patients with this new disease.
Many patients have completely stopped registering for these procedures.
This has had a huge impact on medical device companies including Johnson & Johnson, and during the flu pandemic, pharmaceutical companies have basically performed well in terms of sales.

Johnson & Johnson’s 2020 revenue was US$82.
58 billion, failing to reach its operating target of US$86.
2 billion.
However, this figure is the same as the revenue of 82 billion U.
S.
dollars in 2019, and it also marks Johnson & Johnson's victory in the challenge of the epidemic.
As for Gorsky, his total compensation includes salaries worth $1.
65 million, stock and option awards totaling more than $18 million, cash incentive compensation of more than $3 million, and pensions worth $6.
43 million.

Although Johnson & Johnson's new crown vaccine research and development and the company's business performance are good, Gorsky's remuneration plan in 2020 still makes some investors dissatisfied.
They believe that because Johnson & Johnson defended itself in thousands of opioid and talc lawsuits, Gorsky was spared $9 billion in legal costs.
Plaintiffs across the United States sued Johnson & Johnson, claiming that its talc powder is carcinogenic, and places across the United States took it to court for the company's opioid marketing.

04 Hui Zhi Robert Coury: 29.
06 million US dollars

After experiencing a series of setbacks during the COVID-19 pandemic, the large-scale merger of Mylan and Pfizer's Upjohn subsidiary finally ended in November 2020 and created a new generic drug giant Viatris.

Huizhi executive chairman Robert J.
Coury will receive a salary of US$29.
06 million in 2020.

Robert J.
Coury, the former CEO of Mylan, was previously hired as executive chairman to lead the company through a turbulent merger during the pandemic.
In addition, Coury also received a cash award of US$4.
41 million, which was established under the leadership of Mylan, and his salary remained at US$1.
8 million.
As part of the chairman's generous salary in 2021, Coury will receive an annual incentive bonus of 150% of the annual salary and a long-term incentive bonus of 600% of the annual salary.

Most of Coury's income comes from a stock award of $12.
45 million and a one-time cash bonus of $10 million.
The company’s annual report shows that this huge bonus far exceeds the bonuses of other executives, partly because Coury joined Mylan as an executive in April this year, but did not receive an annual equity grant worth 10.
8 million US dollars at that time.
Viatris also praised Coury for "playing an important leadership role in analysis and negotiation" during the merger, and praised him for "unexpectedly stepping up his efforts" during the COVID-19 pandemic.

Coury is no stranger to generous compensation agreements.
In 2016, he resigned as executive chairman of Mylan and received a jaw-dropping $97 million bonus, far exceeding the bonuses received by CEOs of other large pharmaceutical companies.
Some investors were very angry at Coury's generous salary, and they tried to get him out of the chairmanship.

In fact, Coury's $29.
06 million salary is more than five times the total salary of Viatris' new CEO, Michael Goettler.
As for the company’s CEO, Goettler, Viatris said that Goettler’s salary in Viatris will be substantially increased to 1.
3 million US dollars, when Goettler’s salary in Pfizer’s Upjohn department as CEO was 825,000 US dollars.

05 AbbVie Richard Gonzalez: $24 million

For AbbVie CEO Richard Gonzalez, he faces a daunting task: he must prepare for the Humira biosimilar that AbbVie will launch in the United States in 2023.
So far, he is looking for new sources of income to fill this gap, and progress seems to be going well.

，150，Humira201958%202043%。SkyriziRinvoq。，2020，23.
2，。

Gonzalez2020。20202400，2019216011%。330，1440，490。16.
516.
9。

SkyriziRinvoq，，。，RinvoqDupixent；SkyriziCosentyx，。2025100150。

06 David Ricks：2370

，Dave Ricks，。

David Ricks2017，。10。

2017，Ricks158420202370。CEO，20。

Ricks？

，2020，“，()”。FDA，RetevmoLyumjev，Taltz、CyramzaOlumiant。，317，。

Ricks2017，，，，。，。

，2020，Ricks148.
3，262.
5。1360。600。

07 Ken Frazier：2209

2，Ken Frazier，Robert Davis。

Frazier20202209，20192765。，1080，470。，Frazier220，201950%。

Frazier 202055%230。

，Keytruda144，30%。，Keytruda202030%，：Keytruda？

，，。2020，27ArQuleBTK，27.
5VelosBio，(ADC)。

，，COVID-19。COVID-19“”，Ridgeback Bio，。4，，COVID-19molnupiravir，3。

，3，molnupiravirCOVID-19。，，ThemisOncoImmune，COVID-19。

08 Horizon Therapeutics Timothy Walbert：2163

Timothy Walbert，56%，，、BMS、AZCEO。HorizonTimothy Walbert，HorizonTepezza。

Horizon，20201，tepezzaFDA，（TED），TepezzaFDATED。20208.
2，CDMOTepezza，，。

HorizonKrystexxa，4.
06，19%。Horizon，。

，Timothy Walbert2008Horizon，Horizon。、700，11、22200。

09 Pascal Soriot：1545（2152）

Pascal Soriot2019185016.
2%，2018147345.
96%。AZ“”，，Pascal Soriot20213%184。

Pascal Soriot，AZPascal Soriot，“，77%，。”

2020，AZ，43.
28，36%；，17.
76，48%；PD-L1，20.
42，39%。

，Pascal SoriotAZ2020394，2020，2021Q3，，AZMNC TOP10。

，Pascal Soriot2021，AZ“”，AZ，，AZ。

10 Albert Bourla：2103

2020Albert Bourla，，BioNTech，Albert Bourla2020。

According to Pfizer’s annual report, the CEO’s salary in 2020 is approximately US$21.
03 million, an increase of 6.
7% from the US$19.
7 million in 2019.
The base salary is $1.
65 million, and it receives $5.
49 million in cash incentives and approximately $14 million in Pfizer stock options.

Pfizer's 2020 financial report shows that Pfizer's total revenue is 41.
9 billion U.
S.
dollars.
If the performance of Puqiang is excluded, it will increase by 2% compared with last year.
Its Prevnar13 pneumonia vaccine, with sales of 5.
85 billion U.
S.
dollars in 2020, is Pfizer's highest revenue product; sales of the new crown vaccine are 154 million U.
S.
dollars, and sales in 2021 are expected to reach 26 billion U.
S.
dollars.

Pfizer's new crown vaccine production is in fact in full swing.
Its quarterly report shows that the new crown vaccine brought 3.
5 billion US dollars in revenue in the first quarter, and it is expected to provide 300 million doses to the United States by the end of July and to the European Union throughout 2021.
Provide 600 million doses.

11 BMS Giovanni Caforio: USD 2015 million

2020 is the sixth year that Giovanni Caforio has served as CEO of BMS, and his annual salary has exceeded the $20 million mark for the first time.
This milestone can be attributed to his 21-year tenure at BMS and the BMS board of directors that 2020 is its most successful year.

In 2020, BMS announced that it has successfully completed the USD 13.
1 billion acquisition of MyoKardia.

It is reported that MyoKardia is a clinical-stage biomedical company dedicated to discovering and developing targeted therapies for severe cardiovascular diseases.
Through this acquisition, Bristol-Myers Squibb will obtain its new drug mavacamten, which is a potential "first-in-class" cardiovascular drug for the treatment of obstructive hypertrophic cardiomyopathy (HCM).
The drug has obtained the breakthrough therapy qualification granted by the FDA, and the potential patient population in the United States is as high as 200,000, ranking third in EvaluatePharma's list of new drugs with the greatest potential.

The sales of BMS's main products also performed well in 2020.
The multiple myeloma drug Revlimid brought in revenue of 12.
1 billion U.
S.
dollars, an increase of 12% over the previous year.
Eliquis, a blood thinner, can reduce the risk of coagulation in patients with new coronary pneumonia, with sales reaching US$9.
2 billion, an increase of 16% over the previous year.

Although the sales of O drug was only 7 billion U.
S.
dollars, a decrease of 3% from 2019, the drug received five new indication approvals, including approval for the combination with Yervoy for first-line non-small cell lung cancer.
The next round of competition for medicine has laid the foundation.

12 Amgen Robert Bradway: US$21.
3 million

Robert Bradway's annual salary of $2,13 million has increased slightly compared to 1960 in 2019.
This includes a salary of US$1.
65 million, stock and option awards of US$14.
4 million.
A cash prize of 3.
5 million U.
S.
dollars, and his other remuneration totaling nearly 600,000 U.
S.
dollars.

In fact, he has been raising his salary since he became the CEO of Amgen in 2012, because Amgen has been striving to maintain a balance between the generic drug challenge of its products and the growth of new product sales, and is committed to improving its introduction of new drugs and Sales of self-developed new drugs increased.

The data shows that Bradway is leading Amgen to reinvigorate and focus on expanding markets outside the United States.
The most representative is that Amgen has begun to enjoy China's pharmaceutical innovation dividend.
In 2020, Amgen has completed a capital increase of US$421 million in BeiGene, and its shareholding in BeiGene has reached about 20%.
In 2020, Amgen achieved revenue of 25.
42 billion US dollars, an increase of 9% year-on-year.

13 Gilead Daniel O'Day: $18.
99 million

The arrival of Daniel O'Day in 2019 can be regarded as a “fighting order” for Gilead.
At that time, Gilead was in an embarrassing period when the hepatitis C market was shrinking sharply and sales fell for four consecutive years.
The arrival of Daniel O'Day helped Geely's sales increase slightly to 22.
4 billion U.
S.
dollars and reached 24.
7 billion U.
S.
dollars in 2020.

Although his annual salary in 2020 is US$18.
99 million, which is a decrease of US$10 million from the US$29.
1 million in 2019, US$14.
2 million in his 2019 salary is used to compensate him for leaving Roche.

In 2020, Geely's largest revenue comes from the great efficacy of Redecive in the treatment of new coronary pneumonia, with annual sales of 2.
811 billion yuan, accounting for more than 10% of total revenue.

In 2020, Daniel O'Day also led Geely to acquire Immunomedics for US$21 billion and harvested the new breast cancer drug Trodelvy.
The drug's sales in the last two quarters of 2020 reached 136 million U.
S.
dollars, and in April this year, it was approved for new indications for metastatic triple-negative breast cancer and metastatic urothelial cancer.

14 Bojian Michel Vounatsos: 18.
66 million US dollars

Michel Vounatsos's salary in 2020 and his salary in 2019 only increased slightly, rising only 3% to 18.
66 million US dollars.
Among them, the stock incentive increased to 1.
54 million U.
S.
dollars, but the cash reward component of his salary (linked to 2020 performance) decreased by 1.
32 million U.
S.
dollars from the previous year to 2.
57 million U.
S.
dollars.

It is reported that Bojiancai's 2020 revenue has fallen by 6.
5% to US$13.
44 billion.
The main reason is the decline in sales of its core products.
Although the multiple sclerosis product Tecfidera is still the mainstay, accounting for 59% of its revenue, it fell 8% year-on-year; the sales of the star single product Spinraza was US$2.
05 billion, also down 2% year-on-year; Only the biosimilar business had revenue of US$795 million, an increase of 8% year-on-year.

However, the progress of aducanumab's registration review for Alzheimer's disease, which has received much attention from the outside world and has experienced twists and turns, is not satisfactory.
The FDA expert advisory committee opposed and questioned the clinical benefits of the drug.
In the latest discussion, 0 votes agreed.
, 10 votes against, 1 abstention, and finally the review was postponed again.
The FDA is expected to make a final decision on whether to approve or reject Aducanumab on June 7, 2021.

15 BioMarin Jean-Jacques Bienaimé: 18.
12 million US dollars

Jean-Jacques Bienaimé's salary in 2020 has decreased slightly compared to 2019, mainly due to the reduction of cash incentives.
This reduction is mainly due to the suspension of the FDA's listing of its new drug valoctocogene roxaparvovec, which is expected to become the first gene therapy for hemophilia.

On August 19, 2020, the FDA sent a CRL to BioMarin due to concerns about the durability of the drug, and has not yet approved the drug's marketing authorization application.
Once the news was announced, BioMarin's stock price fell sharply, with a drop of 35.
28%, which caused the market value of BioMarin to instantly evaporate billions.

This directly caused the CEO's cash reward to drop from US$2.
32 million in 2019 to US$1.
66 million.

Nevertheless, the European listing application of valoctocogene roxaparvovec has been submitted, and the approval is in progress.
Based on this, BioMarin Jean was also rated as one of the most worthy acquisitions of Biotech by the American analysis agency.